サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1416334

生物製剤受託開発市場レポート：2030年までの動向、予測、競合分析

Biologics Contract Development Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日: | 発行: Lucintel | ページ情報: 英文 150 - page report | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

生物製剤受託開発市場レポート：2030年までの動向、予測、競合分析
出版日: 2024年01月29日
発行: Lucintel
ページ情報: 英文 150 - page report
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

生物製剤受託開発動向と予測

世界の生物製剤受託開発市場は、2024年から2030年までのCAGR 11.5%で、2030年までに推定409億米ドルに達すると予想されています。この市場の主な促進要因は、製薬会社による医薬品開発手続きの数の増加、先進技術の採用の増加、新興諸国での臨床試験に有利な環境です。世界の生物製剤受託開発市場の将来は、腫瘍、免疫疾患、心血管疾患、血液疾患の市場での機会があり、有望に見えます。

生物製剤受託開発市場に関する洞察

Lucintelは、タンパク質発現に哺乳類細胞の採用が増加しているため、予測期間中引き続き哺乳類がより大きなセグメントになると予測しています。これは、ネイティブ構造を実現する正しい翻訳後修飾を備えた哺乳類タンパク質を開発することによって大きな利点をもたらします。

この市場では、治療需要の高まりにより、研究開発やアウトソーシングへのさらなる投資が促進されているため、腫瘍が引き続き最大のセグメントとなるでしょう。

北米は、研究開発投資の増加、臨床試験の需要の高まり、この地域における大手企業の存在により、予測期間を通じて最大の地域であり続けると予想されます。

よくある質問

Q1.市場規模は：

A1.世界の生物製剤受託開発市場は、2030年までに推定409億米ドルに達すると予想されています。

Q2.市場の成長予測は：

A2.世界の生物製剤受託開発市場は、2024年から2030年にかけて11.5%のCAGRで成長すると予想されています。

Q3.市場の成長に影響を与える主な促進要因は：

A3.この市場の主な促進要因は、製薬会社による医薬品開発手続きの増加、先進技術の採用の増加、新興諸国での臨床試験に有利な環境です。

Q4.市場の主要セグメントは：

A4.生物製剤受託開発市場の将来は、腫瘍、免疫疾患、心血管疾患、血液疾患の市場での機会があり、有望に見えます。

Q5.市場の主要企業は：

A5.主要な生物製剤受託開発会社の一部は次のとおりです。

  • WuXi Biologics
  • Abzena
  • Fujifilm Diosynth Biotechnologies
  • KBI Biopharma
  • AGC Biologics
  • Thermo Fisher Scientific
  • Curia Global
  • Genscript
  • Bionova Scientific
  • BioXcellence

Q6.今後、最大となる市場セグメントは：

A6.Lucintelは、タンパク質発現に哺乳類細胞の採用が増加しているため、予測期間中引き続き哺乳類がより大きなセグメントになると予測しています。これは、ネイティブ構造を実現する正しい翻訳後修飾を備えた哺乳類タンパク質を開発することによって大きな利点をもたらします。

Q7.市場において、今後5年間に最大になると予想される地域は：

A7.北米は、研究開発投資の増加、臨床試験の需要の高まり、この地域における大手企業の存在により、予測期間を通じて最大の地域であり続けると予想されます。

Q8.レポートのカスタマイズは可能か：

A8.はい、Lucintelは追加費用なしで10%のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界の生物製剤受託開発市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界の生物製剤受託開発市場の動向（2018-2023）と予測（2024-2030）
  • ソース別の世界の生物製剤受託開発市場
    • 微生物
    • 哺乳類
    • その他
  • 製品サービス別の世界の生物製剤受託開発市場
    • 細胞株の開発
    • プロセス開発
    • その他
  • 疾患適応別の世界の生物製剤受託開発市場
    • 腫瘍
    • 免疫疾患
    • 心血管疾患
    • 血液疾患
    • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別の世界の生物製剤受託開発市場
  • 北米の生物製剤受託開発市場
  • 欧州の生物製剤受託開発市場
  • アジア太平洋の生物製剤受託開発市場
  • その他地域の生物製剤受託開発市場

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会分析
    • ソース別の世界の生物製剤受託開発市場の成長機会
    • 製品サービス別の世界の生物製剤受託開発市場の成長機会
    • 疾患適応別の世界の生物製剤受託開発市場の成長機会
    • 地域別の世界の生物製剤受託開発市場の成長機会
  • 世界の生物製剤受託開発市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界の生物製剤受託開発市場の能力拡大
    • 世界の生物製剤受託開発市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • WuXi Biologics
  • Abzena
  • Fujifilm Diosynth Biotechnologies
  • KBI Biopharma
  • AGC Biologics
  • Thermo Fisher Scientific
  • Curia Global
  • Genscript
  • Bionova Scientific
  • BioXcellence
目次

Biologics Contract Development Trends and Forecast

The future of the global biologics contract development market looks promising with opportunities in the oncology, immunological disorder, cardiovascular disorder, and hematological disorder markets. The global biologics contract development market is expected to reach an estimated $40.9 billion by 2030 with a CAGR of 11.5% from 2024 to 2030. The major drivers for this market are rising number of drug development procedures by pharmaceutical companies, growing adoption of advanced technologies, and favorable environment for clinical trials in the developing countries.

A more than 150-page report is developed to help in your business decisions.

Biologics Contract Development by Segment

The study includes a forecast for the global biologics contract development by source, product service, disease indication, and region.

Biologics Contract Development Market by Source [Shipment Analysis by Value from 2018 to 2030]:

  • Microbial
  • Mammalian
  • Others

Biologics Contract Development Market by Product Service [Shipment Analysis by Value from 2018 to 2030]:

  • Cell Line Development
  • Process Development
  • Others

Biologics Contract Development Market by Disease Indication [Shipment Analysis by Value from 2018 to 2030]:

  • Oncology
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others

Biologics Contract Development Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Biologics Contract Development Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies biologics contract development companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the biologics contract development companies profiled in this report include-

  • WuXi Biologics
  • Abzena
  • Fujifilm Diosynth Biotechnologies
  • KBI Biopharma
  • AGC Biologics
  • Thermo Fisher Scientific
  • Curia Global
  • Genscript
  • Bionova Scientific
  • BioXcellence

Biologics Contract Development Market Insights

Lucintel forecasts that mammalian will remain the larger segment over the forecast period due to increasing adoption of mammalian cells for protein expression, which provides a major advantage by developing mammalian proteins with correct post-translational modifications that delivers a native structure.

Within this market, oncology will remain the largest segment due to growing demand for therapy, which encourages more investments in research and development and outsourcing.

North America will remain the largest region over the forecast period due to growing R&D investments, rising demand of clinical trials, and presence of major players in the region.

Features of the Global Biologics Contract Development Market

Market Size Estimates: Biologics contract development market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Biologics contract development market size by source, product service, disease indication, and region in terms of value ($B).

Regional Analysis: Biologics contract development market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different sources, product services, disease indication, and regions for the biologics contract development market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the biologics contract development market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the biologics contract development market size?

Answer: The global biologics contract development market is expected to reach an estimated $40.9 billion by 2030.

Q2. What is the growth forecast for biologics contract development market?

Answer: The global biologics contract development market is expected to grow with a CAGR of 11.5% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the biologics contract development market?

Answer: The major drivers for this market are rising number of drug development procedures by pharmaceutical companies, growing adoption of advanced technologies, and favorable environment for clinical trials in the developing countries.

Q4. What are the major segments for biologics contract development market?

Answer: The future of the biologics contract development market looks promising with opportunities in the oncology, immunological disorder, cardiovascular disorder, and hematological disorder markets.

Q5. Who are the key biologics contract development market companies?

Answer: Some of the key biologics contract development companies are as follows:

  • WuXi Biologics
  • Abzena
  • Fujifilm Diosynth Biotechnologies
  • KBI Biopharma
  • AGC Biologics
  • Thermo Fisher Scientific
  • Curia Global
  • Genscript
  • Bionova Scientific
  • BioXcellence

Q6. Which biologics contract development market segment will be the largest in future?

Answer: Lucintel forecasts that mammalian will remain the larger segment over the forecast period due to increasing adoption of mammalian cells for protein expression, which provides a major advantage by developing mammalian proteins with correct post-translational modifications that delivers a native structure.

Q7. In biologics contract development market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growing R&D investments, rising demand of clinical trials, and presence of major players in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the biologics contract development market by source (microbial, mammalian, and others), product service (cell line development, process development, and others), disease indication (oncology, immunological disorders, cardiovascular disorders, hematological disorders, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Biologics Contract Development Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Biologics Contract Development Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Biologics Contract Development Market by Source
    • 3.3.1: Microbial
    • 3.3.2: Mammalian
    • 3.3.3: Others
  • 3.4: Global Biologics Contract Development Market by Product Service
    • 3.4.1: Cell Line Development
    • 3.4.2: Process Development
    • 3.4.3: Others
  • 3.5: Global Biologics Contract Development Market by Disease Indication
    • 3.5.1: Oncology
    • 3.5.2: Immunological Disorders
    • 3.5.3: Cardiovascular Disorders
    • 3.5.4: Hematological Disorders
    • 3.5.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Biologics Contract Development Market by Region
  • 4.2: North American Biologics Contract Development Market
    • 4.2.2: North American Biologics Contract Development Market by Disease Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others
  • 4.3: European Biologics Contract Development Market
    • 4.3.1: European Biologics Contract Development Market by Source: Microbial, Mammalian, and Others
    • 4.3.2: European Biologics Contract Development Market by Disease Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others
  • 4.4: APAC Biologics Contract Development Market
    • 4.4.1: APAC Biologics Contract Development Market by Source: Microbial, Mammalian, and Others
    • 4.4.2: APAC Biologics Contract Development Market by Disease Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others
  • 4.5: ROW Biologics Contract Development Market
    • 4.5.1: ROW Biologics Contract Development Market by Source: Microbial, Mammalian, and Others
    • 4.5.2: ROW Biologics Contract Development Market by Disease Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Biologics Contract Development Market by Source
    • 6.1.2: Growth Opportunities for the Global Biologics Contract Development Market by Product Service
    • 6.1.3: Growth Opportunities for the Global Biologics Contract Development Market by Disease Indication
    • 6.1.4: Growth Opportunities for the Global Biologics Contract Development Market by Region
  • 6.2: Emerging Trends in the Global Biologics Contract Development Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Biologics Contract Development Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Biologics Contract Development Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: WuXi Biologics
  • 7.2: Abzena
  • 7.3: Fujifilm Diosynth Biotechnologies
  • 7.4: KBI Biopharma
  • 7.5: AGC Biologics
  • 7.6: Thermo Fisher Scientific
  • 7.7: Curia Global
  • 7.8: Genscript
  • 7.9: Bionova Scientific
  • 7.10: BioXcellence